A) C) B) - Cancer Research · 10 HGC27 MKN45 control cisplatin * ** Fig.Suppl 6 Santos et al.,...
7
A) C) D) F) Fig.Suppl 1 Santos et al., Cancer Research AGS pLKO sh1 PARP1 Caspase 3 pLKO sh1 pLKO sh1 0 25 50 75 100 125 150 d0 d1 d3 d5 cell number (1x10 3 ) *** *** AGS 0 1 2 3 4 5 6 7 MKN45 pLKO sh1 sh2 0 1 2 3 4 5 6 7 MKN45 pLKO sh1 sh2 Number of PARP1 + cells (%) Number of daspase 3 + cells (%) *** * * * E) AGS MKN45 sh2 sh2 AGS MKN45 C- pLKO sh1 SOX9 β-actin AGS B) 0 0,2 0,4 0,6 0,8 1 1,2 MKN45 pLKO sh1 sh2 ** ** SOX9 (Fold change) pLKO sh1 20x 40x 20x 20x pLKO sh1 AGS 0 2 4 6 MKN45 pLKO sh1 sh2 *** *** Number of p-H3 + cells (%) MKN45 sh2 p-H3 (Ser10) 20x G)
Transcript of A) C) B) - Cancer Research · 10 HGC27 MKN45 control cisplatin * ** Fig.Suppl 6 Santos et al.,...
A) C)
D)
F)
Fig.Suppl 1 Santos et al., Cancer Research
AGS
pLK
O
sh1
PARP1 Caspase 3
pLK
O
sh1
pLK
O
sh1
0
25
50
75
100
125
150
d0 d1 d3 d5
cell
num
ber (
1x10
3 )
***
*** AGS
0
1
2
3
4
5
6
7
MKN45
pLKO sh1 sh2
0
1
2
3
4
5
6
7
MKN45
pLKO sh1 sh2
Num
ber o
f PA
RP
1+ c
ells
(%)
Num
ber o
f das
pase
3+
cells
(%)
***
* * *
E) AGS MKN45
sh2
sh2
AGS MKN45
C- pLKO sh1
SOX9
β-actin
AGS B)
0
0,2
0,4
0,6
0,8
1
1,2
MKN45
pLKO sh1 sh2
** **
SO
X9
(Fol
d ch
ange
)
pLKO
sh1
20x 40x
20x 20x
pLK
O
sh1
AGS
0
2
4
6
MKN45
pLKO sh1 sh2
*** ***
Num
ber o
f p-H
3+ c
ells
(%)
MKN45
sh2
p-H3 (Ser10)
20x
G)
A) pL
KO
sh
1
AGS
0
1
2
3
4
MKN45
pLKO sh1 sh2
*
***
sh2
MKN45
Fig.Suppl 2 Santos et al., Cancer Research
B)
0
0,2
0,4
0,6
0,8
1
1,2
pLKO sh1 sh2
* *
MKN45
C-M
YC
(Fol
d ch
ange
)
D)
MKN45 cells pLKO sh1 sh2
1x106
5/5 (100 %)
5/6 (83 %)
2/4 (50 %)
1x105
10/12 (83 %)
5/12 (41 %)
0/8 (0 %)
1x104
3/6 (50 %)
1/6 (16 %)
0/4 (0 %)
Num
ber o
f SA
-β-G
al+
cells
(%)
SA-β-Gal
E)
0
1
2
3
p21 CD44
pLKO sh2
mR
NA
(Fol
d ch
ange
)
*
≠
MKN45
AGS
pLK
O
shβ-
cate
nin
Caspase 3 PARP1 SA-β-Gal p-H3 (Ser10)
40x
C)
Fig.Suppl 3 Santos et al., Cancer Research
Fig.Suppl 4 Santos et al., Cancer Research
A) β-catenin
904
cont
rol
695
AGS MKN45
β-catenin co
ntro
l 90
4 69
5
B)
cont
rol
904
695
pLKO sh1 sh2
β-catenin MKN45 cells
0
25
50
75
100
control 904 695
control sh1 sh2
0
5
10
15
20
25
30
35
control 904 695
control sh1 sh2
HGC27
β- catenin accumulation quantification
% o
f pos
itive
cel
ls
C)
*** ***
*** *** **
**
AGS MKN45
*
*
* * *
* *
40x 20x
40x
0
1
2
3
4
AGS HGC27
control 904 695
Fig.Suppl 5 Santos et al., Cancer Research
A) 90
4 co
ntro
l 69
5
*
* *
**
B)
904
cont
rol
695
C)
0,0
0,5
1,0
1,5
2,0
904 control 695 742
**
** ***
0
0,5
1
1,5
2
2,5
3
control 904 695
pLKO sh1 sh2
p-H
3+ c
ells
(rel
ativ
e nu
mbe
r)
***
* *
* * *
***
MKN45
904
cont
rol
695
pLKO sh1 sh2 74
2
***
AGS p-H3 (Ser10)
Num
ber o
f p-H
3+ c
ells
(%)
MKN45 p-H3 (Ser10)
p-H
3+ c
ells
(rel
ativ
e nu
mbe
r)
40x
20x
20x
0
1
2
3
4
5
healthy HP- HP+ tumor
SO
X9
(Fol
d ch
ange
)
D)
A)
0
2
4
6
8
10
HGC27 MKN45
control cisplatin
***
Fig.Suppl 6 Santos et al., Cancer Research
B)
MKN45 KATO III
cont
rol
10 µ
M
1 µM
10x
AGS HGC27 MKN45 KATO III
cont
rol
10 µ
M
1 µM
AGS HGC27
40x
MK
N45
C
ispl
atin
-R
p-H3 (Ser10)
40x
Num
ber o
f p-H
-3 +
cel
ls (%
)
pLKO cisplatin
pLKO
sh1
sh1 cisplatin
SOX9
control
SOX9 cisplatin
C)
Fig.Suppl 7 Santos et al., Cancer Research
C)
A) B)
